Values First Advisors’s Mirum Pharmaceuticals MIRM Stock Holding History

Values First Advisors’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$868K	Sell	9,397 -7,027	-43%	-$661K	0.45%	62
2025 Q4	$1.3M	Sell	16,424 -2,288	-12%	-$164K	0.67%	46
2025 Q3	$1.37M	Sell	18,712 -920	-5%	-$58.5K	0.73%	46
2025 Q2	$999K	Buy	19,632 +1,514	+8%	+$67.4K	0.54%	55
2025 Q1	$818K	Sell	18,118 -1,722	-9%	-$81.2K	0.48%	56
2024 Q4	$820K	Sell	19,840 -3,885	-16%	-$162K	0.45%	62
2024 Q3	$925K	Buy	23,725 +3,971	+20%	+$158K	0.5%	54
2024 Q2	$675K	Sell	19,754 -1,654	-8%	-$43.4K	0.4%	67
2024 Q1	$538K	Buy	21,408 +4,668	+28%	+$128K	0.32%	93
2023 Q4	$494K	Sell	16,740 -21,179	-56%	-$641K	0.3%	108
2023 Q3	$1.2M	Buy	+37,919	New	+$1.04M	0.77%	41
2023 Q2	–	Sell	-8,497	Closed	-$204K	–	269
2023 Q1	$204K	Buy	+8,497	New	+$194K	0.13%	134

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Values First Advisors's MIRM Position: Q1 2026 in Review

Values First Advisors reduced its Mirum Pharmaceuticals (MIRM) stake by 43% in Q1 2026, selling an estimated $661K and leaving 9,397 shares worth $868K. The position accounts for 0.45% of the portfolio, ranked #62.

Values First Advisors first reported a position in MIRM in Q1 2023 and has held it in 12 quarters since. The position peaked at $1.37M in Q3 2025. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

Values First Advisors held 9,397 shares of Mirum Pharmaceuticals worth $868K as of Q1 2026.
Values First Advisors sold 7,027 Mirum Pharmaceuticals shares in Q1 2026, an estimated $661K.
Mirum Pharmaceuticals made up 0.45% of Values First Advisors's portfolio in Q1 2026, its #62 holding.
Values First Advisors first reported a position in Mirum Pharmaceuticals in Q1 2023 and has held it in 12 quarters since.
Values First Advisors's Mirum Pharmaceuticals position peaked at $1.37M in Q3 2025.
311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on Values First Advisors's 13F filing for Q1 2026, filed 17 Apr 2026.